Category Archives: Platelet Rich Plasma Injections


Platelet rich plasma and thicker hair | Empty Nest – NorthFulton.com

Everyone would like to have thicker hair. Well, almost everyone -- but our focus today is not on those rare unicorns whose complaint is that their hair is just too thick, too luxurious and too lustrous. This article is for the rest of us who would like to have more or thicker hair or at least stop losing what we have.

A number of treatment options have been the staple considerations for normal male and female pattern hair loss for years. For men, finasteride, minoxidil and hair transplantation have long been the most effective interventions. Womens treatment options used to be even more limited, with minoxidil alone being the main option for female pattern hair loss. However, a growing body of research supports that hormone replacement and/or platelet rich plasma injections could be the miracle grow for failing follicles!

First, a note about hormone replacement therapy: A physician named Dr. Glaser published an article in the British Journal of Dermatology in 2012 which made an observation that has unfortunately gained little attention likely because it runs counter to how people usually think about hair loss and testosterone. Dr. Glaser surveyed 285 women who had been on subcutaneous testosterone therapy for more than a year for the treatment of androgen deficiency and 63% of the women who had reported hair thinning prior to treatment reported hair thickening after treatment began. This finding has received little attention, but a 63% response rate deserves further investigation.

Several patients in my own clinic who complained of thinning hair, went on androgen replacement prescribed by their endocrinologist or ob-gyn for other reasons. These patients hair became markedly thicker and more voluminous on testosterone. Although Premier Dermatology does not offer hormone replacement therapy (HRT), androgen levels are one of the laboratory tests that we order as part of our screening panel for causes of hair loss. If we have a female hair loss patient with low androgen levels (either low or low normal), we offer referral to a physician who performs HRT for discussion of risks and benefits of a trial of androgen replacement therapy for hair loss. Results that we have seen have paralleled the 63% response rate that Dr. Glaser published.

Second and just as exciting, Platelet Rich Plasma, also known as PRP, is an option that is fast becoming an important treatment strategy for treating hair loss in both men and women, be it for common hair thinning or for certain alopecia syndromes. PRP is a blood product derived from a patients own blood. The process involves the following: A fraction of blood (up to 22ml in our practice) is drawn from the individual patient into a syringe (depends on the extent of hair loss). This is a relatively small amount compared to blood donation. The blood then is spun in a centrifuge to separate its components (White & Red Blood Cells, Platelet Rich Plasma and Platelet Poor Plasma). The Platelet Rich Plasma (PRP) is collected into a syringe. The PRP is then injected into a treatment area (the scalp for hair loss).

The basis behind PRP is that growth factors and other proteins within platelets promote healing and induce tissue regeneration and rejuvenation. Platelets contain growth factors and biologically active molecules that are normally released when platelets are outside of blood vessels such as when a person gets a cut and starts to bleed into surrounding tissue. Injecting PRP into the subdermal fat induces platelet degranulation (release of platelet contents) which causes tissue exposure to platelet growth factors. In plain terms, PRP delivers growth factors to stimulate hair follicles.

To achieve best results, PRP is performed in a series of treatments. Typically, two to three treatments are performed once per month initially. It is often recommended that treatments take place every 6 months after the initial series of treatments to continue hair regeneration and maintain or enhance results.

PRP has numerous other applications in dermatology the most common of which is as an adjunct to microneedling for skin rejuvenation or treatment of acne scars. However, PRPs greatest potential may be as a treatment to help grow or maintain hair.

At Premier Dermatology and Mohs Surgery of Atlanta, we are committed to offering scientifically-backed, effective and state of the art treatments. Kathryn Filipek, PA-C has extensive cosmetic, surgical and medical dermatology experience and is responsible for the hair loss branch of our practice. If you are interested in exploring PRP and hair loss options, call today to make an appointment with Ms. Filipek. It is our privilege to take care of you and your familys skin, vein, and hair care needs.https://premierdermatologyatlanta.com/

Link:
Platelet rich plasma and thicker hair | Empty Nest - NorthFulton.com

Joint Pain Injections Market Size 2020 | Covid 19 Impact Analysis | Global Industry Trends, Growth, Share, Size and Forecast – StartupNG

Market Scenario of the Joint Pain Injections Market:

The industry study on Joint Pain Injections outlines national and global business prospects and competitive scenarios for Joint Pain Injections. Estimation of market size and projections were given based on a unique research design tailored to the complexities of the Joint Pain Injections.

Sample Copy of This Report @ https://www.quincemarketinsights.com/request-sample-65228?utm_source=SNG/KK

The prominent players covered in this report: Anika Therapeutics, Inc., Bioventus, Ferring Pharmaceuticals Inc., Sanofi, Zimmer Biomet.

Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, And South America.

The Joint Pain Injections market has been segmented By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections)By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint). Also, key factors impacting the growth of the Joint Pain Injections market have been identified with potential gravity.

Years Covered in the Study:

Historic Year: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Year: 2028

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-65228?utm_source=SNG/KK

The Joint Pain Injections market report comprises domestic and global markets. This study on Joint Pain Injections market compiles internationally influential players and their business strategies to understand industry strategies. Some points that are the highlights are:

Reasons for buying this report:

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-65228?utm_source=SNG/KK

About Us:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact Us:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read more here:
Joint Pain Injections Market Size 2020 | Covid 19 Impact Analysis | Global Industry Trends, Growth, Share, Size and Forecast - StartupNG

Porzingis hoping to play again this season if Mavs can get past Clippers – The Official Home of the Dallas Mavericks – Mavs.com

Kristaps Porzingis isnt quite sure if the lateral menisus tear in his right knee will eventually require surgery. But the Dallas Mavericks forward is holding out hope that it wont.

An MRI performed earlier this week revealed the tear, and Porzingis said he had been taking some Platelet-Rich Plasma (PRP) injections to help alleviate the pain.

Were hoping with the injections that it could help me, Porzingis said on Saturday. Hopefully the meniscus can kind of I dont know how it works exactly but repair itself with the injections.

But it depends on how Im going to feel in the next two weeks and then I think the medical staff is going to make a decision whether I need that (surgery) or not.

One thing is for sure: Porzingis wont play in Game 6 of the Mavs Western Conference quarterfinals series against the Los Angeles Clippers. The game tips off Sunday at 2:30 p.m. inside the NBA bubble with the Clippers leading the series, 3-2.

Porzingis also hasnt been medically cleared to play if the series between the Mavs and Clippers reaches a Game 7.

My hope is that if we have a chance to advance (to the conference semifinals), maybe somehow I can get the knee better and play, Porzingis said. I tried to go now and practice, and it just wasnt the medical staff just didnt accept me playing and doing more.

So for now, I dont know. Im going to be here, because if I was able to play through it, then maybe I can keep playing through it at some point. Just now Im doing intense treatment and doing all I can to improve the knee, and then well see where we go.

Porzingis said he originally injured his knee while battling for an offensive rebound in the first half of Game 1 of this series. But he continued to play in that game, and in the ensuing two contests before missing the past two games.

I think somebody kind of fell on (the knee), Porzingis said. I think it was (Marcus) Morris (Sr.), on accident, obviously, and I felt something in my knee. But I just kept playing through it, and then at halftime I told the medical staff my knee was bothering me a little bit.

They worked on it and I was good to go in the second half, and thats when I got ejected and then my knee locked up after Game 1. Somehow we were able to get it going (for Game 2) it felt good.

However, Porzingis said in Game 3 his knee got worse. And just before the tipoff of Game 4, the pain in his knee was so excruciating that Porzingis was a last-minute scratch.

Right before the game (4) I just couldnt get anything going and its super disappointing, super frustrating, he said. But Ive learned how to accept that feeling and look forward to whats next.

Porzingis has learned how to accept that feeling because of what happened to him on Feb. 6, 2018. Thats the day Porzingis tore his left anterior cruciate ligament after landing awkwardly following a dunk in a road game against the Milwaukee Bucks while he was playing for the New York Knicks.

Porzingis underwent surgery on Feb. 13, 2018, was traded to the Mavs on Jan, 31, 2019, and made his Mavs debut on opening day this season.

So as far as knee injuries go, Porzingis has been there, done that. And the Mavs hope his right knee responds favorably to treatment and hell be able to play if they can somehow win two more games against the Clippers.

The door is not closed on the entire season if we are able to advance, coach Rick Carlisle said. When I spoke to you (media) guys on Wednesday about this, he had practiced, he was sore. It was clear that hes doing everything that he can.

The guys been doing treatment, I dont know, 10 hours a day. . .and it just wasnt progressing the way that he had hoped. He was on the floor today and did some shooting and did a little bit of moving around, so he wants to keep the door open to possibly play if we can move on, but its a very tough situation, but hes trying his best.

Someone asked Porzingis if he was worried about his future in the NBA due to injuries to each of his two knees, or if he thought these were just isolated incidents. His response?

I cant really be too worried about that, Porzingis said. Both of (the injuries) were contact injuries, and these things happen. What I can do is focus on the work that I can put in to make sure that I decrease the possibility of that happening.

That means strengthening everything and just trying to do all of the preventive work I can, and thats in my hands. Again, its a contact sport and these things can happen, so I cant be too frustrated over these kinds of things.

At the time of his injury, Porzingis was playing some of the best basketball of his career. Overall, the 7-3, 240-pounder averaged 20.4 points, 9.5 rebounds and 2.0 blocks per game this season.

Also, Porzingis had 34 points and 13 rebounds in Game 3 against the Clippers. Its the first time a member of the Mavs produced a 30-point, 10-rebound game in the postseason since Dirk Nowitzki collected 34 points and 11 rebounds in Game 3 of the 2011 NBA Finals against the Miami Heat.

Clearly, Porzingis is a major centerpiece to what the Mavs are trying to get accomplished.

Obviously I was (feeling) bad for a little bit for a little while once I found out what happened in the knee, Porzingis said. But I was able to accept that feeling and move past that pretty quickly and look into whats next and go on from there. Obviously if this is the end for my season, it has a bitter end, although I think my year as it went on I got into a better rhythm and I started playing better basketball with each game.

I feel like now once I go into the offseason and make sure I get the knee healthy, Im looking forward to just thinking picking up where I left off and keep playing that high level of basketball and look forward to the next things we can accomplish as a team.

Still, Porzingis shrugs at the mere thought that he may have played his last game this season.

Ive got to thank the medical staff, he said. They put in crazy hours with me and in the treatment room and in the weight room. But at this point it was just a little too much maybe, and they dont want me to push it any more, so were here and were going day-by-day.

Its hard to not be able to be out there with the guys and fight, especially in a series like this thats so much fun. Its really tough and frustrating, but it is what it is and now Im looking forward to getting healthy.

Twitter: @DwainPrice

More here:
Porzingis hoping to play again this season if Mavs can get past Clippers - The Official Home of the Dallas Mavericks - Mavs.com

When your hair falls off and leaves scars – The Star, Kenya

The texture was different. In fact, my remaining hair seemed to look like the hair of our Muslim sisters. It was soft and light, something that was quite different from my natural hair, she said.

But she said even with the texture change, her hair began falling off and only a little was left at the back of her head.

There were patches on my head which turned into wounds. When I slept at night, I could wake up and find my hair on the pillow. This left me worried. When I combed my hair, the hair fell off, she said.

Onyinge then decided to braid her hair to see if the falling off would be tamed.

This did not work. I then decided to do weaves or wear wigs as I sought for a solution, she said.

An adults head has 100,000150,000 hair follicles, and each follicle can grow about 20 individual hairs. On average, every normal individual loses 75 to 100 hairs a day.

In 2016, Onyinge could not walk with her hair, whether it was braided or not.

Painful wounds began forming in the patches that were now scars. The hair was now not growing anymore. This is the time I decided to go and see a specialist, who recommended some lotions that I was to apply on my head, she said.

The pain on the wounds reduced but the hair continued to fall off.

LOST HOPE

The specialist told Onyinge that whatever condition it was, it must have been inherited.

I went to the specialist to repair my hair but then he asked me if anybody in my family had the same problem. This is the time I had to tell him about my father and my sister, she said.

It was at this point that she was given a lotion to apply on her hair, which did not guarantee that her hair would grow.

The doctor first drew blood from my system and extracted plasma, which was used to inject my scalp. I had 15 injections on my scalp just as a way to treat my hair loss, she said.

Trichologist Hillary Onyango says that the plasma used for the injection should be able to stimulate the growth of the hair follicles.

Though she had to part with around Sh15,000 per session, Onyinge said the hair continued to fall off.

Then a few days ago, a friend told me he knew a good doctor who could help me with the condition. I decided to give it a shot. When I arrived, I realised the clinic was being run by a man and his wife, all from Indian origin, she said.

Continue reading here:
When your hair falls off and leaves scars - The Star, Kenya

Joint Pain Injections Market Size By Product Analysis, By Application, By End-Users, By Regional Outlook, By Top Companies and Forecast to 2027 -…

Sanofi S.A

Joint Pain Injections Market Segment Analysis-

The research report includes specific segments by Type and Application. Each type provides information about the production during the forecast period of 2015 to 2027. The application segment also provides consumption during the forecast period of 2015 to 2027. Understanding the segments helps in identifying the importance of different factors that aid market growth.

Joint Pain Injections Market, By Application

Shoulder & Elbow Knee & Ankle Spinal Joints Hip Joint Others

Joint Pain Injections Market, By Type

Steroid Joint Injections Hyaluronic Acid Injections Platelet-rich Plasma (PRP) Injections Placental Tissue Matrix (PTM) Injections Others

Joint Pain Injections Market, By Distribution Channel

Hospital Pharmacies Online Pharmacies Retail Pharmacies

The study analyses the following key business aspects:

Analysis of Strategies of Leading Players: Market players can use this analysis to gain a competitive advantage over their competitors in the Joint Pain Injections market.

Study on Key Market Trends: This section of the report offers a deeper analysis of the latest and future trends of the Joint Pain Injections market.

Market Forecasts:Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Joint Pain Injections market.

Regional Growth Analysis:All major regions and countries have been covered in the report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.

Segmental Analysis:The report provides accurate and reliable forecasts of the market share of important segments of the Joint Pain Injections market. Market participants can use this analysis to make strategic investments in key growth pockets of the Joint Pain Injections market.

Business Opportunities in Following Regions and Countries:

North America (United States, Canada, and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain, and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia, and Australia)

Latin America (Brazil, Argentina, and Colombia)

How will the report assist your business to grow?

The document offers statistical data about the value (US $) and size (units) for the Joint Pain Injections industry between 2020 to 2027.

The report also traces the leading market rivals that will create and influence the Joint Pain Injections business to a greater extent.

Extensive understanding of the fundamental trends impacting each sector, although greatest threat, latest technologies, and opportunities that could build the global Joint Pain Injections market both supply and offer.

The report helps the customer to determine the substantial results of major market players or rulers of the Joint Pain Injections sector.

Reason to Buy this Report:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the global Joint Pain Injections Market. Highlights key business priorities in order to assist companies to realign their business strategies. The key findings and recommendations highlight crucial progressive industry trends in Joint Pain Injections Market, thereby allowing players to develop effective long term strategies.

Thank you for reading our report. The report is available for customization based on chapters or regions. Please get in touch with us to know more about customization options, and our team will ensure you get the report tailored according to your requirements.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Excerpt from:
Joint Pain Injections Market Size By Product Analysis, By Application, By End-Users, By Regional Outlook, By Top Companies and Forecast to 2027 -...

PRP versus Hyaluronic Acid Injections for Knee OA: Cost-Effectiveness Analysis – DocWire News

A study compared the cost-effectiveness of a series of three intra-articular platelet-rich plasma (PRP) injections versus hyaluronic acid (HA) viscosupplementation to treat symptomatic osteoarthritis (OA) of the knee.

Level one outcome data on PRP or HA injections in symptomatic knee OA patients through 2015 were used to collect health utility values. Costs were calculated using typical charges incurred by symptomatic knee OA patients treated at a large private orthopedic practice with a series of either PRP or HA injections. The health utility values and costs were the basis for an expected-value decision analysis model.

Per the model, the cost per quality-adjusted life year (QALY) of a series of PRP injections was $8,635.23/QALY compared with $5,331.75/QALY for a series of HA injections. While the series of PRP injections had a higher initial cost than the HA injections seriesa $1,433.67 differencethe PRP injections series was more effective, yielding a higher utility value, compared with the HA injections series at one year (0.69 vs. 0.58, respectively; P=0.0062). Using PRP injections instead of HA injections was associated with an incremental cost-effectiveness ratio of $12,628.15/QALY.

While a series of either PRP ($8,635.23/QALY) or HA ($5,331.75/QALY) injections for the treatment of symptomatic knee osteoarthritis would be considered cost-effective (cost/QALY <$50,000), PRP injections were not more cost-effective than HA. However, PRP was significantly more effective at one year, and being associated with an Institute for Clinical and Economic Review of $12,628.15/QALY when compared with HA, a series of PRP injections should be considered a reasonable and acceptable alternative to HA injections for the treatment of symptomatic knee OA, the authors concluded.

Read the original post:
PRP versus Hyaluronic Acid Injections for Knee OA: Cost-Effectiveness Analysis - DocWire News

Lowrie to have injections for knee pain relief – MLB.com

NEW YORK -- Jed Lowrie's 18-month injury saga took another turn on Wednesday, when the team announced the infielder will undergo a series of platelet-rich plasma and stem cell injections. Lowries timeline to return to the Mets will depend upon the outcome of that treatment. Its almost like a progression

NEW YORK -- Jed Lowrie's 18-month injury saga took another turn on Wednesday, when the team announced the infielder will undergo a series of platelet-rich plasma and stem cell injections. Lowries timeline to return to the Mets will depend upon the outcome of that treatment.

Its almost like a progression of injections and well see how everything responds, and [if] the pain goes away and hes able to join us at some point this season, Mets manager Luis Rojas said. Thats the plan.

The injection regimen was presented to Lowrie as a course of therapy after examinations from both Mets physician Dr. David Altchek and an independent, third-party doctor. Lowrie has been unable to play due to PCL laxity, a loosening of a left knee ligament that causes him pain when he runs. Although Lowrie feels some relief from the pain when he wears a rehab brace on his knee, the brace is too large and restricting for him to wear in games.

Until Lowrie can play with a smaller, more mobile brace, he will not come off the 45-day injured list. He is not eligible to come off anyway until Sept. 3.

Lowrie, 36, has taken just eight plate appearances since signing a two-year, $20 million contract in Jan. 2019. He has spent the vast majority of his tenure on the IL due to left knee trouble and a right calf strain. Lowrie initially sustained a sprained left knee capsule in Feb. 2019, before the team revealed that he was also battling more general, undefined left side issues.

Only last month did the Mets announce the updated PCL laxity diagnosis for Lowrie. Rojas said he was unsure if Lowrie, who was unavailable for comment, considered surgery or only the injection regimen.

Even if Lowrie can make it back in September, he will find playing time hard to come by. The Mets feature a crowded middle infield with Amed Rosario, Andrs Gimnez, Robinson Can and others all jockeying for reps. J.D. Davis has become the starter at third base, one of Lowries primary positions, while Gimnez has developed into an early National League Rookie of the Year candidate at second and short. Given his physical issues, it seems unlikely Lowrie would contribute anywhere other than at designated hitter, which is Dominic Smiths primary position.

From the trainers room Starting pitcher Michael Wacha (right shoulder inflammation) restarted a throwing program Tuesday at Citi Field, playing catch at distances up to 75 feet. He felt better, according to Rojas, but he will miss at least two starts on the IL. For now, Robert Gsellman has taken Wachas rotation spot.

Can (left adductor strain) could return from the IL as soon as hes eligible on Friday. Can was scheduled to play in a simulated game Wednesday at the Mets alternate site in Brooklyn, which Rojas called another step ahead for the veteran second baseman. When Can returns, the Mets will have to be creative to find playing time for Gimnez.

Shortstop sidelined Rosario was out of the lineup for a second straight game on Wednesday due to the lingering effects of a stomach bug, though he was available off the bench. Gimnez filled in at shortstop.

Everyday Daz The key to Edwin Dazs recent run of success out of the bullpen? Pitching more often.

When the Mets removed Daz from the closers role last week, he requested that the team use him more frequently than once every four or five days. Rojas listened, deploying Daz five times in a 10-day stretch from Aug. 2-11, and the reliever responded with 10 strikeouts and one walk over five scoreless innings.

Now that Ive been pitching more consecutively and more often, I feel like my pitches are all sharp, Daz said through an interpreter. But in regards to closing, thats not my decision. Im open to pitching whatever inning they tell me to come in -- whether its the sixth, seventh, eighth -- it doesnt matter to me. As long as they put the ball in my hands, Ill be ready to help the team.

Since Dazs unofficial demotion, Rojas has exclusively turned to Seth Lugo in save situations. The team is taking a committee approach, however, making it possible for Daz to garner more save chances again if he keeps pitching well.

Anthony DiComo has covered the Mets for MLB.com since 2007. Follow him on Twitter @AnthonyDiComo, Instagram and Facebook.

Read the original post:
Lowrie to have injections for knee pain relief - MLB.com

Yes, People Are Reportedly Losing Hair Due to Stress From the Pandemic – POPSUGAR

As the year progresses and the novel coronavirus continues to upend everyday life, there's still a lot more we're learning about the virus and its side effects. For example, recent research has shown that hair loss is common among those who have recovered from the virus even actress Alyssa Milano revealed via Twitter that her hair has been falling out in clumps following her experience with COVID-19 though it also appears to be a common experience among those who haven't contracted the virus but are affected by the stress of the pandemic directly.

"I'm based in California, so the reopening of our salons has been a slower process than most states," celebrity hairstylist Carrera Alvarez told POPSUGAR. "One thing I'm hearing from my clients is concern about hair loss from stress, which is very real. We're living in a superstressful time, and that can lead to [potentially] losing more hair."

This type of hair loss is known as telogen effluvium, which, as a previous POPSUGAR article says, is "caused by physiologic stress to the body following conditions like anemia, low iron, surgery, general anesthesia, changes in hormones, or others." It's essentially stress-related hair loss, and it happens when the hair is pushed into the resting phase but doesn't enter the growth phase following a highly stressful event. "Anything that your body deems a stress physical or psychological will cause a person to develop a telogen effluvium," dermatologist Sapna Palep, MD, told POPSUGAR.

Dr. Palep has experienced telogen effluvium five times so far; two of them occurred after giving birth, while the others happened after three separate stressful events. According to her, most stress-related hair loss can linger for up to six months following whatever triggered it and can take up to one full year for the hair to recover. The good news is that this type of hair loss is usually temporary and can be treated with topical products and in-office procedures.

"In my office, I treat patients with hair loss with PRP (platelet-rich plasma) therapy, which uses injections of a concentration of a patient's own platelets to restore and accelerate hair growth," Dr. Palep said. "Treatments are done once a month for three months and every six months thereafter for maintenance. It's highly effective, and I've undergone PRP therapy myself for my hair loss."

If PRP isn't as accessible for you, both Alvarez and Dr. Palep have alternative hair-loss treatments they'd recommend turning to. "My go-to is Nioxin. It's the number one brand for thinning hair and known globally as a trusted brand," Alvarez said. "I start [my clients] on a System Kit to create a solid foundation for healthy growing hair." Meanwhile, Dr. Palep is a big fan of Nutrafol and the results it's been proven to show.

"I think it has a unique grouping of ingredients compared to its competitors," she said. For topical therapy, though, Dr. Palep recommends using Midoxil. "It's available without a prescription as a two percent solution, a five percent solution, and a five percent foam," she said. "I typically recommend five percent because studies support that it has somewhat greater efficacy. It works by increasing the window of time that a hair follicle is in its anagen (growth) phase, shortening the window of the telogen (resting/nongrowing) phase, and enlarging miniaturized follicles."

Continue reading here:
Yes, People Are Reportedly Losing Hair Due to Stress From the Pandemic - POPSUGAR

Joint Pain Injections Market 2020-2028 Covid-19 Updates With Key Players Anika Therapeutics, Inc., Bioventus – Owned

Joint Pain Injections Market Scenario 2020-2028:

This detailed market study covers Joint Pain Injections Market growth potentials which can assist the stake holders to understand key trends and prospects in Joint Pain Injections market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the markets growth potential, which can help investors identify scope and opportunities. The analysis also provides details of each segment in the global Joint Pain Injections market

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-65228?utm_source=PF/komal

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: Anika Therapeutics, Inc., Bioventus, Ferring Pharmaceuticals Inc., Sanofi, Zimmer Biomet.

According to the report, the Joint Pain Injections market report points out national and global business prospects and competitive conditions for Joint Pain Injections. Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Joint Pain Injections. The Joint Pain Injections market has been Segmented By Type of Injection (Steroid Joint Injections, Hyaluronic Acid Injections, Platelet-rich Plasma (PRP) Injections, Placental Tissue Matrix (PTM) Injections), By Application (Shoulder & Elbow, Knee & Ankle, Spinal Joints, Hip Joint). Historical background for the demand of Joint Pain Injections has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand Joint Pain Injections have also been established with potential gravity.

Joint Pain Injections

Regional segmentation and analysis to understand growth patterns: The market has been segmented in major regions to understand the global development and demand patterns of this market. By region, the Joint Pain Injections market has been segmented in North America, Europe, Asia Pacific, Middle East & Africa, and South America. The North America and Western Europe regions are estimated to register a stable demand during the forecast period with market recovery from recent slowdowns.

North America region includes the US, Canada, and Mexico. The US is estimated to dominate this market with a sizeable share followed by Canada, and Mexico. The industrial sector is a major contributor to the US and Canada economies overall. Hence, the supply of advanced materials in production activities is critical to the overall growth of industries in this region.

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-65228?utm_source=PF/komal

Europe region is dominated by Germany, the UK, France, Italy, and Spain. These countries also have a strong influence on the industrial sector resulting in sizeable demand for Joint Pain Injections market. Asia Pacific is estimated to register the highest CAGR by region during the forecast period. The presence of some of the high growth economies such as China and India is expected to propel the demand in this region. Besides, this region has witnessed strategic investments by major companies to increase their market presence. The Middle East and Eastern Europe are estimated to be other key regions for the Joint Pain Injections market with a strong market potential during the forecast period. Rest of the World consisting of South America and Africa are estimated to be emerging markets during the forecast period.

This report provides: 1) An overview of the global market for Joint Pain Injections market and related technologies. 2) Analysis of global market trends, yearly estimates and annual growth rate projections for compounds (CAGRs). 3) Identification of new market opportunities and targeted consumer marketing strategies for global Joint Pain Injections market. 4) Analysis of R&D and demand for new technologies and new applications 5) Extensive company profiles of key players in industry.

The researchers have studied the market in depth and have developed important segments such as product type, application and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

If Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-65228?utm_source=PF/komal

Objectives of this report: To estimate market size for Joint Pain Injections market on regional and global basis. To identify major segments in Joint Pain Injections market and evaluate their market shares and demand. To provide a competitive scenario for the Joint Pain Injections market with major developments observed by key companies in the historic years. To evaluate key factors governing the dynamics of Joint Pain Injections market with their potential gravity during the forecast period.

About US: QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact US: Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

Read the original here:
Joint Pain Injections Market 2020-2028 Covid-19 Updates With Key Players Anika Therapeutics, Inc., Bioventus - Owned

Another Nice Thing We Can’t Have in 2020: Shohei Ohtani’s Pitching – FanGraphs

The list of things that havent gone according to plan in 2020 is long enough to reach to the moon and back, and to that, we can add the return of Shohei Ohtani to competitive pitching. After more than a year spent recovering from Tommy John surgery, the 26-year-old wonders reacquaintance with the mound was hotly anticipated, but after two brief and miserable outings, hes injured, and Angels manager Joe Maddon said on Tuesday that he doesnt expect to see Ohtani pitch again this year.

On Sunday, Ohtani made his second start of the season, and it began with promise, as he retired the top of the Astros lineup George Springer, Jose Altuve, and Alex Bregman in order on a total of eight pitches. He topped 95 mph a few times with his four-seamer, struck out Springer swinging at a splitter, and induced Altuve to pop up a bunt foul. Heres the Springer strikeout:

Things were looking up, particularly given that in his July 26 start against the As, Ohtani failed to retire any of the six hitters he faced, yielding three hits, three walks, and five runs. Though he dialed his fastball as high as 97.1 mph in the second inning on Sunday, he labored and grew visibly frustrated while walking the bases loaded on 26 pitches. He went to two strikes on six consecutive hitters, squandering 0-2 counts twice before striking out Kyle Tucker and Jack Mayfield. By the time he walked both Dustin Garneau and Springer, he had thrown 42 pitches in the inning a ridiculously high number in any context, let alone one for a pitcher in his second start back from surgery. His three fastballs to Springer in the second inning failed to break 90 mph; belatedly, Maddon gave him the hook, bringing in Jose Rodriguez, who retired Altuve via a groundout.

I thought it was fatigue, from where I was standing, said Maddon of Ohtanis rough second inning. We were trying to get him out there as quickly as we could at that point. There was also the chance that he could get through it, and then I wasnt certain if hed be able to continue or not. It was one of those cusp situations. I thought he was just out of his delivery at that point.

Once removed, however, Ohtani complained of discomfort in his forearm, prompting an MRI exam. He was diagnosed with a Grade 1-2 strain of his flexor pronator mass, which helps in part to explain why his average fastball velocity has been so far removed from 2018 (93.8 mph vs. 97.4, via Pitch Info). Hell be shut down from throwing for four to six weeks, which likely would not leave him enough time to build up to game activity on the mound. He will remain available to serve as a designated hitter, though for the moment hes considered day-to-day, like the rest of us.

Im not anticipating him pitching at all this year, Maddon told reporters on Tuesday. In whatever kind of throwing program, itll be very conservative. I dont have any projection on that other than hes not going to pitch this year.

This is a heartbreaker. Ohtani dazzled the baseball world with a nine-start run in early 2018, before a blister and then elbow soreness sidelined him in early June. Diagnosed with a Grade 2 sprain of his ulnar collateral ligament, he underwent both both platelet-rich plasma and stem-cell injections, but lasted just 2.1 innings in his return to the mound on September 2. Soon after that, doctors recommended that he undergo Tommy John surgery, which he did in October 2018. He returned to the majors on May 7 of last season, and spent the remainder of the year splitting his time between rehabbing his throwing arm and serving as a DH, but in September it was discovered that he needed surgery on his left knee to repair a bipartite patella, a congenital issue that had been aggravating him throughout the season. In his injury-bookended campaign, Ohtani hit .286/.343/.505 with 18 homers and 12 steals in 425 PA before being shut down, a very good performance but a step down from his .285/.361/.564 (151 wRC+) as a rookie.

The knee surgery delayed Ohtanis post-Tommy John rehab program, but he finally completed it in December, after which he was shut down until spring training. The plan as of February was that he would return to the mound in mid-May, pitching once a week, and that he would have an innings limit. The coronavirus pandemic delayed those plans but he started the Angels third game of the season, and there was plenty of optimism that he could help the teams quest to reach the postseason for the first time since 2014.

Now, if hes going to do it, hell have to do so as the primary DH. So far, things havent gone that well for Ohtani on that side of the ball, either; hes hitting .148/.179/.407 with two homers, one walk, and nine strikeouts in 28 PA. Despite those ugly numbers, hes actually making good contact, with an average exit velocity of 91.7 mph, an xwOBA of .382, and an xSLG of .642.

The Angels rotation will be the poorer without Ohtani, though the other five pitchers who have started (Dylan Bundy, Andrew Heaney, Griffin Canning, Matt Andriese, and Patrick Sandoval, the last two of whom have taken just one start apiece) have combined for a 3.45 ERA and 3.00 FIP thus far. The return of Julio Teheran, who arrived in camp late after testing positive for COVID-19, will help compensate for Ohtanis loss; hell make his Angels debut on Wednesday, starting against the Mariners, but even so, the rotation ranks just 19th in the majors in our projection-driven Depth Charts, suggesting that the units current overperformance which has still only led to a 4-7 record thus far may be fleeting.

The Angels still view Ohtani as a legitimate two-way player, but should they? His total body of work on major league mounds now amounts to 12 outings spread over three seasons, with three appearances totaling four innings since June 6, 2018. Recall that he also made just five starts for the Nippon Ham Fighters in 2017, his final year in NPB, due to a right ankle injury that required surgery. In other words, hes thrown just 78.2 competitive innings over four seasons, with the previous three ending with an injury that required surgery, and hell head into another offseason with health questions. Thats a lot of work and a lot of rehab with only a minimal payoff, and it has come with roster issues that the Angels have had to work around days off before and after his starts, and extra rest between starts, necessitating some rotation juggling. With a healthy Ohtani playing every day in an outfield alongside Mike Trout and Jo Adell (who made his major league debut on Tuesday night, going 1-for-4 with an infield single that showed off his elite speed), that unit might be the best in baseball and the cornerstone of a contender.

On the other hand, Ohtani has shown that he has high-quality stuff on the mound, this years struggles notwithstanding. He pitched to a 3.31 ERA and 3.57 FIP with a 29.1% strikeout rate in 2018, and Sundays first inning suggested that he can still get good hitters out even if hes not dialing it up to 100 mph. A player who can put up All-Star caliber rate stats as both a pitcher and a hitter is a once-in-a-century talent; Ohtanis high-level performance as both a pitcher and hitter has only early Babe Ruths 1918 and 19 seasons as a precedent. To give up on that simply so that Maddon has an everyday DH or outfielder to write into the lineup feels like using a Van Gogh painting as a TV tray.

Maddon told reporters he still believes Ohtani can be a two-way player. We just got to get past the arm maladies and figure that out, he said. Hes such a high-end arm and, of course, what he can do in the batters box. It might get to the point where he may choose to want to do one thing over the other and just express that to us.

So far as anybody knows, thats not the case yet, and in a normal six-month season, Ohtanis forearm strain would be viewed as a setback, not a crossroads. He wont be able to help the Angels as a pitcher during this brief, weird season, but thats not enough of a reason to surrender the possibility that he could return to dazzling the baseball world with his unique combination of talents.

We hoped you liked reading Another Nice Thing We Cant Have in 2020: Shohei Ohtanis Pitching by Jay Jaffe!

Please support FanGraphs by becoming a member. We publish thousands of articles a year, host multiple podcasts, and have an ever growing database of baseball stats.

FanGraphs does not have a paywall. With your membership, we can continue to offer the content you've come to rely on and add to our unique baseball coverage.

Support FanGraphs

Original post:
Another Nice Thing We Can't Have in 2020: Shohei Ohtani's Pitching - FanGraphs